Performance Evaluation of Plasma Sample Types on the ADVIA Centaur® System and Atellica® IM Analyzers*
Leipold H, Thakur K, Freeman J.
Siemens Healthcare Diagnostics Inc., Tarrytown, NY, U.S.

Comparison of Hemoglobin Variants across Siemens Healthineers HbA1c Assays†
Tyler A, Schaible C, Robinson C, Gisiora J, Jones J, Cheek J.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.

Performance Evaluation of the ADVIA Centaur® Androstenedione Assay‡
2. Siemens Healthcare Diagnostics Inc., Walpole, MA, U.S.

Performance Evaluation of the HIL Feature on the Atellica® CH Analyzer
Garcia E, Davis J, Snyder JT, Cheek J.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.

Multicenter Study of the Mid-volume Sysmex® CS-2500 System Compared to the Sysmex® CA-1500 System Using Reagents from Siemens Healthineers†
1. Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany
2. Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.
3. Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum,
   Institut für Laboratoriums- und Transfusionsmedizin, Bad Oeynhausen, Germany
4. Washington University School of Medicine, Saint Louis, MO, U.S.
5. Florida Hospital, Orlando, FL, U.S.
6. Columbia University, Medical Center, New York, NY, U.S.
7. Haemostasis Center, University Hospitals Giessen and Marburg, Germany
8. Duke University, Durham, North Carolina, U.S.
9. University of Michigan, Ann Arbor, MI, U.S.
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>A-283</td>
<td>Multicenter Study of the High-volume Sysmex® CS-5100 System Compared to the Sysmex® CA-1500 System Using Reagents from Siemens Healthineers†</td>
<td>Heisig M†, Gueney B†, Biddle R, Rechner A†, Kahl M†, Barten R†, Wagner A†, Birschmann I†, Eby C†, Francis JL†, Hod E†, Kemkes-Matthes B†, Ortel TL†, Pipe SW.†</td>
<td>1. Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2. Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3. Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Institut für Laboratoriums- und Transfusionsmedizin, Bad Oeynhausen, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4. Washington University School of Medicine, Saint Louis, MO, U.S.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5. Florida Hospital, Orlando, FL, U.S.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6. Columbia University, Medical Center, New York, NY, U.S.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>7. Haemostasis Center, University Hospitals Giessen and Marburg, Germany</td>
</tr>
<tr>
<td>A-294</td>
<td>Performance of the INNOVANCE® Heparin Assay for the Quantitative Determination of the Activity of Unfractionated Heparin and Low-molecular-weight Heparin in Plasma Using a Single Calibration Curve for Both Heparin Types Employing Four Different Coagulation Analyzers†</td>
<td>Wilkens M, Lange S, Merz M, Bussfeld D.</td>
<td>Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2. Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2. University of Maryland School of Medicine, Baltimore, MD, U.S.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4. Baylor Scott &amp; White Health Center, Temple, TX, U.S.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5. University Hospital Tuebingen, Tuebingen, Germany</td>
</tr>
</tbody>
</table>
Tuesday, August 6, 9:30 a.m.–5 p.m.

A-424 Performance Evaluation of the Atellica® IM HIV Ag/Ab Combo (CHIV) Assay†
Padda NK,1 Anostario M,1 Conarpe C,1 Plouffe B,1 Brown C,1 Carter GA,1 Saharig-Romero E,1 Guidon P,1 Bostanian Z,2 Mohammad AA,3
1. Siemens Healthcare Diagnostics Inc., Tarrytown, NY, U.S.
2. Research and Development Institute, Van Nuys, CA, U.S.
3. Scott and White Memorial Hospital, Temple, TX, U.S.
Siemens Healthineers supported the study by providing systems, reagents, as well as compensation for services provided for clinical trials.

A-430 Performance Evaluation of the Atellica® IM HIV 1/O/2 Enhanced (EHIV) Assay††
Seck S,1 Anostario M,1 Conarpe C,1 Plouffe B,1 Fonstad R,1 Saharig-Romero E,1 Guidon P,1 Mohammad AA,2 Bostanian Z.3
1. Siemens Healthcare Diagnostics Inc., Tarrytown, NY, U.S.
2. Scott and White Memorial Hospital, Temple, TX, U.S.
3. Research and Development Institute, Van Nuys, CA, U.S.
Siemens Healthcare Diagnostics Inc. supported the study by providing systems, reagents as well as compensation for services provided for clinical trials.

A-444 Performance Evaluation of the ADVIA Centaur® and Atellica® IM Zika Tests§
Singh K, Arroyo J, Mansini M, Patibandla S.
Siemens Healthcare Diagnostics Inc., Tarrytown, NY, U.S.

A-457 Performance Evaluation of ADVIA Centaur® Type-Specific Herpes-1 IgG and Herpes-2 IgG Assays§
Marta Costa
Biokit Research & Development, Barcelona, Spain

A-458 Performance Evaluation of the ADVIA Centaur® EBV-VCA IgM, EBV-VCA IgG and EBV-EBNA IgG Assays§
Marta Costa
Biokit Research & Development, Barcelona, Spain

Wednesday, August 7  9:30 a.m–5 p.m.

B-162 Performance Evaluation of the Atellica® CH TBil_2 Assay to Include Neonates†
Snyder J, Koellhoffer J, Cheek J.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.

B-224 Evaluation of the Correlation of Siemens Healthineers Blood Gas and Clinical Chemistry Systems for Electrolytes and Metabolites††
Bethoney C, Chin S, Fennell S.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.

B-232 Performance Evaluation of the Atellica® CH Urinary/Cerebrospinal Fluid Protein (UCFP) Assay§
Datta P, Louis D, Dai J.
Siemens Healthcare Diagnostics Inc., Glasgow, DE, U.S.

B-233 Performance Evaluation of the ADVIA® Chemistry Urinary/Cerebrospinal Fluid Protein (UCFP) Assay§
Datta P, Hickey P, Dai J.
Siemens Healthcare Diagnostics Inc., Glasgow, DE, U.S.

B-234 Performance Evaluation of the Atellica® CH CYSC_2 Assay
Parker J, Cheek J, Kolewe K, Janas S, Theos C.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.
(continued)
Performance of the Emit® II Plus Oxycodone Assay on the Dimension Vista® Intelligent Lab Systems
Taiba S, Siefring GE Jr, Israel B, Morjana N.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.

Performance Evaluation of the Atellica® CH NAPA, PROC, and LIDO Assays
Parker J, Cheek J, Kolewe K, Janas S, Boyles Z, Theos C.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.

Performance Evaluation of the Atellica® CH OXY Assay
Parker J, Cheek J, Kolewe K, Janas S, Hay K, Theos C.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.

Performance of the Emit® II Plus Oxycodone Assay on the Dimension® Chemistry Systems
Vassallo J, Siefring GE Jr, Israel B, Morjana N.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.

Performance Evaluation of the ADVIA Centaur® Everolimus§ Assay‡‡
Baxter S,1 Chuang T.2
1. Randox Laboratories Limited, Co. Antrim, United Kingdom
2. Siemens Healthcare Diagnostics Inc., Tarrytown, NY, U.S.

Performance of the Emit® II Plus Oxycodone Assay on the ADVIA® Chemistry Systems
Gabriel B, Siefring GE Jr, Israel B, Morjana N.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.

Performance Evaluation of the ADVIA Centaur® Sirolimus Assay‡‡
Baxter S,1 Chuang T.2
1. Randox Laboratories Limited, Co. Antrim, United Kingdom
2. Siemens Healthcare Diagnostics Inc., Tarrytown, NY, U.S.

Everolimus Assay§ with Automated Pretreatment for the Dimension® Chemistry System
Jie L, Tyler C, Samson L, Wei T.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.

Performance Evaluation of the Emit® II Plus Oxycodone Assay on the Beckman Coulter AU680 System†
Walters A, Israel B, Siefring GE Jr.
Siemens Healthcare Diagnostics Inc., Newark, DE, U.S.

* Use of assay on plasma specimens is in development
† Product availability may vary from country to country and is subject to varying regulatory requirements
‡ Information about this device is preliminary. Safety and effectiveness for the uses discussed have not been established. The device is under development and not commercially available. Future availability cannot be ensured.
§ Under development. The performance characteristics of this device have not been established. Not available for sale. Product availability will vary from country to country and will be subject to varying regulatory requirements
∆ This study was completed as part of product development for Atellica® Process Manager. The first component of this solution is not yet released, and is planned to be released as part of Atellica® Process Manager Version 2.1. The second component was developed during the feasibility phase of product development for the Atellica® Process Manager Version 2.1 and is also not yet released.
** Not available for sale in the U.S.
†† The products/features mentioned here may not be commercially available in all countries. Due to regulatory reasons, their future availability cannot be guaranteed.
‡‡ Assay under development by Randox Laboratories Ltd. for Siemens Healthcare Diagnostics Inc. Not available for sale. Future availability cannot be guaranteed.